Requip/Requip XL (Parkinson’s Disease) - Forecast and Market Analysis to 2022

GlobalData
March 31, 2014
60 Pages - GLDATA18028
$3,495.00

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

GlaxoSmithKline’s Requip (ropinirole) was first launched in 1997 in certain European markets (France, UK) for Parkinson’s disease and restless legs syndrome. For Parkinson’s disease, it is approved for use in early patients as a monotherapy, or for advanced patients as an adjunct to levodopa therapy.

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Requip including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Requip for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Requip performance
- Obtain sales forecast for Requip from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

'

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 20
4.1 Overview 20
4.1.1 Diagnosis - The UK Brain Bank Criteria 20
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.2 Treatment Synopsis 24
4.2.1 Dopaminergic Therapy Classes 24
4.2.2 Treatment of Parkinson’s Disease by Stage 26
4.2.3 Other Treatment Options 29
4.3 Parkinson’s Disease Assessment Scales 29
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 30
4.3.2 Hoehn and Yahr Clinical Staging 32
4.3.3 Other Clinical Assessments 33
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 36
5.3 Dopamine Agonists 37
6 Requip/Requip XL (ropinirole) 38
6.1 Overview 38
6.2 Efficacy 39
6.3 Safety 41
6.4 SWOT Analysis 41
6.5 Forecast 42
7 Appendix 43
7.1 Bibliography 43
7.2 Abbreviations 47
7.3 Methodology 50
7.4 Forecasting Methodology 50
7.4.1 Diagnosed Parkinson’s Disease Patients 50
7.4.2 Percent Drug-Treated Patients 51
7.4.3 General Pricing Assumptions 51
7.4.4 Compliance Assumptions 52
7.4.5 Individual Drug Assumptions 53
7.4.6 Generic Erosion 54
7.5 Physicians and Specialists Included in this Study 55
7.6 About the Authors 57
7.6.1 Author 57
7.6.2 Global Head of Healthcare 58
7.7 About GlobalData 59
7.8 Disclaimer 59

1.1 List of Tables
Table 1: Symptoms of Parkinson’s Disease 19
Table 2: UK Brain Bank Diagnostic Criteria 21
Table 3: Diagnosis and Treatment Guidelines for Parkinson’s Disease 22
Table 4: Most Prescribed Drugs for Parkinson’s Disease by Class in the Global Markets, 2014 23
Table 5: Dopaminergic Therapy in Parkinson’s Disease 26
Table 6: UPDRS Clinical Assessment of Disease Severity 31
Table 7: Parkinson’s Disease Assessment Scales Used in Clinical Trials 33
Table 8: Treatment of Motor Symptoms in Parkinson’s Disease 35
Table 9: Leading Treatments for Parkinson’s Disease, 2014 36
Table 10: Product Profile - Requip/Requip XL 39
Table 11: Requip/Requip XL SWOT Analysis, 2014 41
Table 12: Global Sales Forecasts ($m) for Requip/Requip XL, 2012-2022 42

1.2 List of Figures
Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 25
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson’s Disease 27

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax